AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2872279
Drug: Alfentanil with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil with neuromuscular blocking agents
Trial: 2872279
Drug: Alfentanil without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil without neuromuscular blocking agents
Trial: 29795315
Drug: Anticonvulsants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsants with sedation-analgesia (SA)
Trial: 29795315
Drug: Anticonvulsants without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticonvulsants without sedation-analgesia (SA)
Trial: 29795315
Drug: No exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No exposure to SA or anticonvulsants
Trial: 19923089
Drug: TACE combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE combined with percutaneous lipiodol and anti-cancer agent injection into the tumor (Group B)
Trial: 17600466
Drug: Rituximab +
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab + chemotherapy (CEOP)
Trial: 17600466
Drug: Chemotherapy (CEOP)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CEOP)
Trial: 11429357
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric ropivacaine (18 mg)
Trial: 11429357
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric bupivacaine (12 mg)
Trial: 9678820
Drug: Mebeverine (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine (135 mg t.d.s.)
Trial: 8036831
Drug: EcSf2a-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcSf2a-2 vaccine (doses ranging from 2.3 to 9.0 x 10(8) CFU, given on days 0, 3, 14, and 17)
Trial: 7887022
Drug: EcSf2a-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcSf2a-2 vaccine
Trial: 6407504
Drug: Fluvoxamine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (mean dose 101 mg/day)
Trial: 6407504
Drug: Imipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (mean dose 127 mg/day)
Trial: 24839916
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day ferrous fumarate plus 1mg/day folic acid (FFFA group)
Trial: 24839916
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day ferrous fumarate alone (FF group)
Trial: 24839916
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day ferrous fumarate (both groups)
Trial: 21857244
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine (group B)
Trial: 21857244
Drug: Oral fentanyl
RxNorm normalized name: fentanyl Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fentanyl (group C)
Trial: 21118495
Drug: ezetimibe +
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ezetimibe + atorvastatin 40 mg
Trial: 26539650
Drug: atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 80 mg
Trial: 17658249
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol fumarate 12 microg twice daily for 14 days
Trial: 16363240
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg daily
Trial: 9456244
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of QFIA and traditional cytology
Trial: 30959472
Drug: Oral cryotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cryotherapy (ice chips) during oxaliplatin infusion
Trial: 28650086
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (IV tPA)
Trial: 25646792
Drug: Infacort (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infacort (oral hydrocortisone granules with taste masking)
Trial: 15505499
Drug: Transdermal GTN
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal GTN (0.6 mg/h/24 hrs for 6 days)
Trial: 9672169
Drug: Interferon-alpha 6
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 6 MU tiw for 8 weeks followed by down-titration (3,1 MU tiw)
Trial: 8062564
Drug: Propofol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (mean loading dose 0.24 mg/kg; mean maintenance dose 0.76 mg/kg/hr)
Trial: 8062564
Drug: Midazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (mean loading dose 0.012 mg/kg; mean maintenance dose 0.018 mg/kg/hr)
Trial: 9186825
Drug: Interferon-ribavirin combination
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Interferon-ribavirin combination therapy (dosage as for monotherapy) for 6 months
Trial: 9186825
Drug: Interferon monotherapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon monotherapy (3 MU 3x/week) for 6 months
Trial: 9186825
Drug: Ribavirin monotherapy
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin monotherapy (1000-1200 mg/day) for 6 months
Trial: 20521308
Drug: Tailored cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored cognitive-behavioral therapy (CBT) and exercise training (16 sessions over 10 weeks)
Trial: 18668592
Drug: Abetimus (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abetimus (100 mg/week for up to 22 months)
Trial: 12897643
Drug: Safinamide 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safinamide 2 mg/kg oral load
Trial: 8890308
Drug: Motor unit
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor unit activity during agonist and antagonist functions
Trial: 6513433
Drug: Verapamil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (40 mg doses p.o./day continuously)
Trial: 6513433
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (61 patients treated without additional verapamil therapy)
Trial: 30810500
Drug: Protein (≥30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein (≥30 g of high-quality protein/meal)
Trial: 22494013
Drug: High stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High stimulation (HS) spinal cord stimulation therapy, controlled with a programmer for a minimum of two hours four times daily.
Trial: 22494013
Drug: Low stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low stimulation (LS) spinal cord stimulation therapy, received above the paresthesia threshold for one min once daily.
Trial: 20028832
Drug: Stress Reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress Reduction Treatment (SRT)
Trial: 17916545
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily plus lansoprazole 30 mg once daily
Trial: 12709721
Drug: CGRP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRP with L‐NMMA (a nitric oxide‐synthase inhibitor)
Trial: 12709721
Drug: CGRP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRP with indomethacin (a cyclooxygenase inhibitor)
Trial: 12709721
Drug: CGRP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRP with tetraethylammonium chloride (TEAC) (a K(+)(Ca)‐channel blocker)
Trial: 12709721
Drug: CGRP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRP with glyburide (INN, glibenclamide) (a K(+)(ATP)‐channel blocker)
Trial: 10604047
Drug: SAM patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAM patch (50 micrograms/day estradiol)
Trial: 10604047
Drug: LR patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LR patch (50 micrograms/day estradiol)
Trial: 10604047
Drug: SAM patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAM patch
Trial: 10604047
Drug: LR patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LR patch
Trial: 7729633
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg three times a day) + Amoxicillin (750 mg three times a day)
Trial: 7729633
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg three times a day) + Placebo (750 mg three times a day)
Trial: 2202163
Drug: 5% cyclosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% cyclosporin in an ointment base under occlusion
Trial: 7408414
Drug: Naloxone 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.8 mg intravenously
Trial: 7408414
Drug: Morphine 15
RxNorm normalized name: morphine 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 15 mg intravenously
Trial: 26787629
Drug: Cholecalciferol 50
RxNorm normalized name: cholecalciferol 50 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 50 000 IU weekly for 8 weeks, then 50 000 IU monthly for 2 months (group A)
Trial: 26787629
Drug: Cholecalciferol 7000
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 7000 IU daily for 8 weeks, then 12 500 IU weekly for 2 months (group B)
Trial: 16925685
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with a cumulative dose of around 41824 IR, equivalent to 1.7 mg of D.p. and 3.0 mg of D.f. allergen for 6 months.
Trial: 9593493
Drug: SDR plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDR plus physical therapy (PT)
Trial: 2244793
Drug: Imipramine hydrochloride
RxNorm normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine hydrochloride maintained at an average dose of 200 mg
Trial: 2244793
Drug: Monthly interpersonal
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly interpersonal psychotherapy
Trial: 28079828
Drug: PHiD-CV primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD-CV primary vaccination and booster dose
Trial: 17915636
Drug: Carbamazepine immediate
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine immediate release tablet formulation 1
Trial: 17915636
Drug: Carbamazepine immediate
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine immediate release tablet formulation 2
Trial: 15334791
Drug: Glimepiride (3+/−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (3+/−1 mg/d)
Trial: 15334791
Drug: Metformin (2500+/−500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2500+/−500 mg/d)
Trial: 19864905
Drug: Toothpaste containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste containing 1,190 mg/kg fluoride as 0.76% SMFP
Trial: 15155420
Drug: AAS administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AAS administration for 8 or 14 weeks
Trial: 15155420
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (200 mg/week) for 8 weeks
Trial: 11477839
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus concentrated Xuefu Zhuyu Pill (CXZP)
Trial: 2665351
Drug: PVRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV vaccine (new inactivated rabies vaccine grown on Vero cells)
Trial: 2665351
Drug: HDCV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDCV vaccine (rabies vaccine cultivated on human diploid cells)
Trial: 30598
Drug: Flunitrazepam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (0.5 mg)
Trial: 6994369
Drug: Meprobamate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meprobamate (200 mg)
Trial: 31328807
Drug: Ivabradine hemisulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine hemisulfate sustained-release tablets 5 mg
Trial: 31328807
Drug: Ivabradine hemisulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine hemisulfate sustained-release tablets 10 mg
Trial: 31328807
Drug: Ivabradine hemisulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine hemisulfate sustained-release tablets 15 mg
Trial: 31328807
Drug: N-desmethyl ivabradine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-desmethyl ivabradine 5 mg
Trial: 31328807
Drug: N-desmethyl ivabradine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-desmethyl ivabradine 10 mg
Trial: 31328807
Drug: N-desmethyl ivabradine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-desmethyl ivabradine 15 mg
Trial: 29033294
Drug: Acetaminophen 4,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 4,000 mg/day
Trial: 11361192
Drug: Ibuprofen 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 1,200 mg/day
Trial: 7803332
Drug: Midazolam (0.15‐0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.15‐0.20 mg/kg)
Trial: 7803332
Drug: Thiopentone (4‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (4‐6 mg/kg)
Trial: 23918455
Drug: Intranasal pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal pulmonary surfactant (PS)
Trial: 21403524
Drug: Quetiapine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (50 mg/day)
Trial: 18179001
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 70% isopropyl alcohol
Trial: 18179001
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg granisetron IV
Trial: 18179001
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic treatment control
Trial: 11135716
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of saline for 12 h (Group A: 169 patients)
Trial: 11135716
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of tranexamic acid, 1 mg x kg(‐1) x h(‐1) for 12 h (Group B: 171 patients)
Trial: 11135716
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of tranexamic acid, 2 mg x kg(‐1) x h(‐1) for 12 h (Group C: 170 patients)
Trial: 9821028
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose of two capsules of Cyclo 3 Fort in the morning
Trial: 9821028
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dose of one capsule of Cyclo 3 Fort morning and noon
Trial: 7978434
Drug: Placebo PO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PO + tetracaine 12 mg IT
Trial: 7978434
Drug: Placebo PO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PO + tetracaine 12 mg IT + fentanyl 10 micrograms IT
Trial: 7978434
Drug: Clonidine 200
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 200 micrograms PO + tetracaine 12 mg IT
Trial: 7978434
Drug: Clonidine 200
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 200 micrograms PO + tetracaine 12 mg IT + fentanyl 10 micrograms IT
Trial: 29202277
Drug: Clobazam (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (0.25, 0.50, or 1.0 mg/kg/d) during lead-in; Clobazam up to 2.0 mg/kg/d (maximum 80 mg/d) during OLE
Trial: 29202277
Drug: Clobazam dosage
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clobazam dosage increase of ≥ 20% during long-term treatment
Trial: 26633145
Drug: Endotracheal tube
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotracheal tube (ETT) with premedication (atropine and morphine)
Trial: 17277392
Drug: Anti-platelet agents
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-platelet agents
Trial: 20422948
Drug: Itraconazole capsule
RxNorm normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole capsule formulation
Trial: 18043456
Drug: 3-day therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day therapy with amoxicillin-clavulanate
Trial: 18043456
Drug: 10-day therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-day therapy with amoxicillin-clavulanate
Trial: 10385765
Drug: Methylprednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (1 g intravenously infused 6 to 12 hours before stenting)
Trial: 8625084
Drug: Helium-neon laser
RxNorm normalized name: neon
DrugBank: Neon (DB11589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helium-neon laser treatment
Trial: 2205527
Drug: Ranitidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (400 mg per day for 5 days)
Trial: 2205527
Drug: Omeprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (80 mg per day for 5 days, 120 mg on the 1st day)
Trial: 22791282
Drug: Non-xylitol treatment
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-xylitol treatment
Trial: 21956721
Drug: OnabotulinumtoxinA (155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA (155 U, 31 injections of 5U each, with an additional 40 U as needed)
Trial: 19695562
Drug: Written treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written treatment manual
Trial: 17146104
Drug: Gabapentin plus
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin plus antidepressant
Trial: 15179390
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with either a headgear or a functional appliance
Trial: 11209119
Drug: Sequential pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pulse therapy with itraconazole (200 mg twice daily for 1 week) followed by terbinafine (250 mg twice daily for 1 week)
Trial: 11209119
Drug: Terbinafine pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine pulse therapy (3 or 4 pulses of terbinafine)
Trial: 28967523
Drug: Bovine-human reassortant
RxNorm normalized name: human-bovine reassortant rotavirus strain G4 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV)
Trial: 10600433
Drug: Parents as
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents as sole agents of change (experimental group)
Trial: 10600433
Drug: Children as
RxNorm normalized name: AZELASTINE HYDROCHLORIDE 205.5 ug NASAL SPRAY, METERED [Children Astepro Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children as sole agents of change (conventional group)
Trial: 2009851
Drug: Four units
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four units of alcohol (approx. 70 mg alcohol/100 ml blood)
Trial: 2009851
Drug: Two units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two units of alcohol (approx. 35 mg alcohol/100 ml blood)
Trial: 2009851
Drug: Nil units
RxNorm normalized name: Ipomoea nil seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nil units of alcohol (less than 5 mg alcohol/100 ml blood)
Trial: 27929673
Drug: Gadoxetate disodium
RxNorm normalized name: Gadoxetate Disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadoxetate disodium (10 mL diluted 1:1 with saline; injection rate, 2 mL/s)
Trial: 27929673
Drug: Gadobenate dimeglumine
RxNorm normalized name: Gadobenate Dimeglumine
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadobenate dimeglumine (0.2 mL/kg; maximum, 20 mL; injection rate, 2 mL/s)
Trial: 22673738
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose macrolides